Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Najoua Lalaoui

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Cell Reports|September 26, 2019
Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3Emma J Petrie, Jarrod J Sandow, Wil I L Lehmann, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Science Translational Medicine|May 20, 2016
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemiaGabriela Brumatti, Chunyan Ma, Najoua Lalaoui, et al.
Elife|December 3, 2014
TNFR1-dependent cell death drives inflammation in Sharpin-deficient miceJames A Rickard, Holly Anderton, Nima Etemadi, et al.
Cell Death & Disease|February 11, 2023
RIPK3 controls MAIT cell accumulation during development but not during infectionTimothy Patton, Zhe Zhao, Xin Yi Lim, et al.
Iscience|July 8, 2022
Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell deathDaniel Frank, Sarah E Garnish, Jarrod J Sandow, et al.
Nature Communications|June 21, 2020
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosisAndre L Samson, Ying Zhang, Niall D Geoghegan, et al.
Immunity|September 10, 2013
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanismJames M Murphy, Peter E Czabotar, Joanne M Hildebrand, et al.
Life Science Alliance|November 12, 2024
Divergent roles of RIPK3 and MLKL in high-fat diet-induced obesity and MAFLD in miceHazel Tye, Stephanie A Conos, Tirta M Djajawi, et al.
Cancer Cell|February 10, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Cell Reports|September 26, 2019
Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3Emma J Petrie, Jarrod J Sandow, Wil I L Lehmann, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Science Translational Medicine|May 20, 2016
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemiaGabriela Brumatti, Chunyan Ma, Najoua Lalaoui, et al.
Elife|December 3, 2014
TNFR1-dependent cell death drives inflammation in Sharpin-deficient miceJames A Rickard, Holly Anderton, Nima Etemadi, et al.
Cell Death & Disease|February 11, 2023
RIPK3 controls MAIT cell accumulation during development but not during infectionTimothy Patton, Zhe Zhao, Xin Yi Lim, et al.
Iscience|July 8, 2022
Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell deathDaniel Frank, Sarah E Garnish, Jarrod J Sandow, et al.
Nature Communications|June 21, 2020
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosisAndre L Samson, Ying Zhang, Niall D Geoghegan, et al.
Immunity|September 10, 2013
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanismJames M Murphy, Peter E Czabotar, Joanne M Hildebrand, et al.
Life Science Alliance|November 12, 2024
Divergent roles of RIPK3 and MLKL in high-fat diet-induced obesity and MAFLD in miceHazel Tye, Stephanie A Conos, Tirta M Djajawi, et al.
Cancer Cell|February 10, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Pageof 5